The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer

Inclusion Criteria: * (1) Confirmed by histopathology and classified as stage IB-IVA cervical cancer patients according to the 2018 FIGO staging criteria; (2) Patients can receive surgical treatment or curative radiotherapy and chemotherapy; (3) Age range from 18 to 80 years old; (4) General condition: ECOG 0-2; (5) At least one measurable lesion (RECIST 1.1 standard); (6) Be able to understand the research plan and voluntarily participate in this study, and sign an informed consent form; (7) Good compliance, able to cooperate in collecting specimens from various nodes and provide corresponding clinical information; (8) Having comprehensive clinical data on imaging and pathology; (9) The estimated survival time of the patient is greater than 3 months; (10) Having sufficient organ and bone marrow functions. Exclusion Criteria: * 1\) Within 5 years, suffering from other malignant tumors or metastatic or recurrent cervical cancer; (2) Has received any tumor treatment plan in the past; (3) Surgical resection or curative radiotherapy and chemotherapy are not acceptable; (4) Unable to follow the determined clinical follow-up period in conjunction with the study for follow-up; (5) Inability to accept or provide specified efficacy evaluation methods such as CT; (6) Suffering from autoimmune diseases; (7) Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders; (8) Subjects with any severe and/or uncontrolled diseases; (9) According to the researchers judgment, there are accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study by the subjects